Laurent F. A. Hennequin
AstraZeneca
Centre de Recherches
Z.I. La Pompelle
B.P. 1050
France
Name/email consistency: high
- Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors. Hennequin, L.F., Ballard, P., Boyle, F.T., Delouvrié, B., Ellston, R.P., Halsall, C.T., Harris, C.S., Hudson, K., Kendrew, J., Pease, J.E., Ross, H.S., Smith, P., Vincent, J.L. Bioorg. Med. Chem. Lett. (2006)
- N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. Hennequin, L.F., Allen, J., Breed, J., Curwen, J., Fennell, M., Green, T.P., Lambert-van der Brempt, C., Morgentin, R., Norman, R.A., Olivier, A., Otterbein, L., Plé, P.A., Warin, N., Costello, G. J. Med. Chem. (2006)
- Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. Hennequin, L.F., Stokes, E.S., Thomas, A.P., Johnstone, C., Plé, P.A., Ogilvie, D.J., Dukes, M., Wedge, S.R., Kendrew, J., Curwen, J.O. J. Med. Chem. (2002)
